Remus Pharmaceuticals IPO Allotment Status Online

The Remus Pharmaceuticals IPO allotment status will be available on May 24, 2023, as per the timeline provided in the red-herring prospectus.

Below are the steps to check Remus Pharmaceuticals IPO allotment status online:

• Visit the Remus Pharmaceuticals IPO allotment status page.
• Click on the green Remus Pharmaceuticals IPO Allotment Status.
• Enter either PAN number, Application Number or DP Client ID of the demat account to check the Remus Pharmaceuticals IPO allotment status.
• Click Search.

Note: The disabled button shows that the allotment is not yet available online.

The allotment result looks like as below:

• PAN No.: AHMLK1898J
• Application No.: RL041213805307
• Name: Mr. Rajveer Singh
• Shares Applied: 40
• Shares Allotted: 40

The expected listing price of Remus Pharmaceuticals IPO depends on many factors including demand, nature of the business, market environment and state of the economy. The Remus Pharmaceuticals IPO grey market premium gives some hint but the actual listing price is difficult to guess.

Remus Pharmaceuticals IPO allotment status is expected on May 24, 2023. Click the green button Remus Pharmaceuticals IPO Allotment Status above to check the allotment. Note the button remains to disable until the allotment is available online.

If Remus Pharmaceuticals IPO oversubscribed in the retail category, the Remus Pharmaceuticals IPO shares will be distributed on a proportionate basis to Retail Individual Investors (RII). Each retail investor will get a minimum of 1 lot subject to the availability of shares in the retail portion. If enough shares are not available, a lottery is drawn to choose the investors.

The Remus Pharmaceuticals IPO shares will get listed on Monday, May 29, 2023. The equity share of Remus Pharmaceuticals Limited will list on NSE SME.

The reason you didn't get the Remus Pharmaceuticals IPO could be:

• IPO become oversubscribed and allotment process is completed through a lottery
• The IPO application got rejected due to mismatch/incomplete information
• The issue price is higher than the bid price. (Always apply on cut-off price).